Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Merz

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Cancers|September 10, 2020
Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-CriteriaMarkus Wennmann, Thomas Hielscher, Laurent Kintzelé, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Hemasphere|March 19, 2024
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?Sebastian Schwind, Lara Bischof, Marius Bill, et al.
Blood Advances|April 7, 2023
Teclistamab impairs detection of BCMA CAR-T cellsBettina Glatte, Kerstin Wenk, Anja Grahnert, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2024
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple MyelomaJanine Kirchberg, Luise Fischer, Patrick Born, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2023
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapyThomas Walter Georgi, Lars Kurch, Georg-Nikolaus Franke, et al.
Blood Advances|October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myelomaTilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Transplantation and Cellular Therapy|May 17, 2026
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple MyelomaNora Grieb, Thomas Wiemers, Patrick Born, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Cancers|September 10, 2020
Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-CriteriaMarkus Wennmann, Thomas Hielscher, Laurent Kintzelé, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Hemasphere|March 19, 2024
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?Sebastian Schwind, Lara Bischof, Marius Bill, et al.
Blood Advances|April 7, 2023
Teclistamab impairs detection of BCMA CAR-T cellsBettina Glatte, Kerstin Wenk, Anja Grahnert, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2024
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple MyelomaJanine Kirchberg, Luise Fischer, Patrick Born, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Journal of Cancer Research and Clinical Oncology|January 20, 2023
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapyThomas Walter Georgi, Lars Kurch, Georg-Nikolaus Franke, et al.
Blood Advances|October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myelomaTilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Transplantation and Cellular Therapy|May 17, 2026
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple MyelomaNora Grieb, Thomas Wiemers, Patrick Born, et al.
Pageof 13